N-acetyltransferase 1*10 genotype in bladder cancer patients.

In a large bladder cancer study in the greater Berlin area with 425 cases and 343 controls, the haplotype N-acetyltransferase 110 (NAT110) was associated with a decreased bladder cancer risk. In a recently published meta-analysis, results of the studies were found to be inconclusive. Therefore, the aim of this study was to investigate the frequency of NAT110 in bladder cancer patients and controls recruited in an area without industries reported to be associated with increased bladder cancer risk. Rs1057126 (1088 T > A) and rs15561 (1095 C > A) were determined in 412 bladder cancer patients and 415 controls without a known history of malignancies. With these two single-nucleotide polymorphisms (SNP), it was possible to distinguish between NAT14 (wild type), NAT13 (1095 C > A), and NAT110 (1088 T > A, 1095C > A). The frequencies of the determined NAT1 haplotypes did not differ markedly between cases and controls: NAT14: 74%, NAT13: 6%, NAT110: 20%. Bladder cancer risk was not significantly modulated by NAT110/10 (OR 1.03, 95% CI 0.71-1.48) but was higher for NAT13/3 genotypes (OR 2.05, 95% CI 1.32-3.21). In contrast to the Berlin study from 2001, data in present study demonstrated that NAT110 haplotype was not associated with a significantly decreased bladder cancer risk. This may be due to local effects in the greater Berlin area, particularly at the time of investigation. The findings of the present study are in agreement with observations of a recently published meta-analysis which also showed no relevant impact of NAT110 haplotype on bladder cancer risk. The impact of the rare NAT13/*3 genotype was significant but this may be attributed to rarity without major practical relevance.